Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and ...

FDA Recall #D-0125-2025 — Class II — November 18, 2024

Recall #D-0125-2025 Date: November 18, 2024 Classification: Class II Status: Ongoing

Product Description

Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and b) 1000-count bottles (NDC 0378-1805-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

Reason for Recall

Superpotent Drug and Subpotent Drug: potency failures obtained

Recalling Firm

Viatris Inc — Canonsburg, PA

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

63,077 bottles

Distribution

Nationwide within the United States and Puerto Rico

Code Information

Lot #: a) 8177078, Exp. Date May 2025; 8168596, Exp. Date Jan 2025 b) 3199313, Exp. Date May 2025; 3194118, Exp. Date Mar 2025; 3186238, Exp. Date Dec 2024; 3209590, Exp. Date Sep 2025; 3199317, Exp. Date May 2025; 3188733, Exp. Date Jan 2025

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated